STEAP1 and neoplasm: Serial BLI revealed rapid disease progression in mice treated with untransduced T cells while those receiving STEAP1-BBζ CAR T cells demonstrated a significant delay in tumor progression (Fig. 3c, d) and extension of survival (97 days versus 31 days, p = 0.0018 by log-rank test, Fig. 3e).